Skip to main content
. Author manuscript; available in PMC: 2011 Mar 30.
Published in final edited form as: Nature. 2010 Sep 30;467(7315):596–599. doi: 10.1038/nature09454

Fig 2. Effect of PLX4032 on COLO205 xenograft tumor growth.

Fig 2

Tumor volume measurements of mice treated by oral gavage with the indicated doses of PLX4032 or vehicle (n=10 for all groups, error bars indicate standard error) are shown.

A. Administration in conventional formulation occurred daily. Exposures measured on day 7 are shown. At the 6, 20 and 20 BID doses, 1/10, 1/10, and 8/10 animals achieved CR, respectively.

B. Administration in the MBP formulation occurred twice daily. At the 25 mg/kg BID dose (blue), 7/10 animals achieved CR and 3/10 animals achieved PR; at the 75 mg/kg BID dose (red), all animals achieved CR.